Company: CERO
Filing Date: 2025-01-21
Form Type: 8-K
Source: 0001213900-25-004756
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On January 17, 2025, CERo
Therapeutics Holdings, Inc. (the “ Company”) received a letter setting forth the determination of a panel convened by Nasdaq
(the “ Nasdaq Panel”) granting the Company’s request for an extension (the “ Extension”) to regain compliance
with certain continued listing requirements of the Nasdaq Stock Market until April 22, 2025 (the “ Extension Date”). The Company
presented its plan (the “ Plan”) for regaining compliance with such requirements at a hearing conducted on December 17, 2025.

As previously disclosed, the
Company has not been in compliance with the $50 million minimum Market Value of Listed Securities requirement (the “ MVLS Requirement”),
the $15 million minimum Market Value of Publicly Held Securities requirement (the “ MVPHS Requirement”) and the $1.00 minimum
Bid Price requirement (the “ Bid Price Requirement”). All applicable automatic grace periods for regaining compliance for such
requirements have expired. The Company’s Plan includes transferring the listing of its securities to the Nasdaq Capital Market,
which permits companies to satisfy a $2.5 million minimum stockholders’ equity requirement in lieu of the MVLS Requirement, and
a lower $1 million MVPHS Requirement, completing a reverse stock split to regain compliance with the Bid Price Requirement and certain
capital raising activities to attain such $2.5 million of stockholders’ equity.

The Extension is subject
to certain conditions, including that the Company regain compliance with the Bid Price Requirement and apply to transfer the listing
of its securities to the Nasdaq Capital Market by January 22, 2025, as well as the provision of certain information prior to the Extension
Date. The Company effected a reverse stock split at a 100 to 1 ratio prior to the open of trading on January 8, 2025 and the closing
price of its common stock on Nasdaq has been above $1.00 on each trading day following such reverse stock split. The Company expects
to submit the application to transfer the listing of its securities to the Nasdaq Capital Market on the date of this Current Report on
Form 8-K. The Company also intends to provide the information required by the Nasdaq Panel’s decision within the timeframe required
thereby. The Company has made substantial progress towards attainment of at least $2.5 million of stockholders’ equity through
the receipt of proceeds of its committed equity facility